Coffee break, Poster and Software session I

Скачать 388.63 Kb.
НазваниеCoffee break, Poster and Software session I
Размер388.63 Kb.
  1   2   3   4   5   6   7   8   9   10   11


Tuesday June 816:00-20:00Registration18:00-20:00Welcome reception    Wednesday June 908:00-08:45Registration08:45-09:00Welcome and Introduction09:00-10:20Physiology based modellingchair: Charlotte Kloft 09:00-09:40Wilhelm HuisingaPhysiologically-based pharmacokinetic/pharmacodynamic modelling, mathematical model reduction and a mechanistic interpretation of simple empirical models 09:40-10:00Emilie HéninSemi-physiological modeling of absorption kinetics: application to diclofenac10:00-10:20Stefan WillmannInvestigation of the Influence of CYP3A4 Inhibition and Renal Impairment on Morphine and M6G Formation after Codeine Administration using Coupled Whole-Body PBPK Modelling10:20-11:50Coffee break, Poster and Software session IPosters in Group I (see below) are accompanied by their presenter11:50-12:30Physiology based modelling (continued)chair: Katya Gibiansky 11:50-12:10Pascal ChanuMechanistic Models to Simulate Dose Response of IgE Suppression Following Dosing of Anti-IgE Monoclonal Antibodies
12:10-12:30Julia KorellDesign of survival studies for red blood cells
12:30-14:00Lunch14:00-15:15Covariate model buildingchair: Mats Karlsson 14:00-14:55Stephen SennTutorial: Covariate complications in clinical trials14:55-15:15Akash KhandelwalCovariate Model Building Using Linear Approximations15:15-16:30Tea break, Poster and Software session IIPosters in Group II (see below) are accompanied by their presenter16:30-17:30Methodologychair: France Mentré 16:30-16:50Brigitte LacroixEvaluating the IPPSE method for PKPD analysis16:50-17:10Dalia KhachmanYou have problems to interpret VPC? Try VIPER!17:10-17:30Bruno BoulangerTrial predictions vs. trial simulations in early clinical development: a framework to evaluate the predictive probability of success based on NONMEM outputsThursday June 1008:45-10:05Lewis Sheiner Student Sessionchairs: Chantal Csajka, Ferdie Rombout, Willi Weber  08:45-09:10Caroline BazzoliDesign evaluation and optimisation in multi-response nonlinear mixed effect models with cost functions: application to the pharmacokinetics of zidovudine and its active metabolite09:10-09:35Maud DelattreEstimation of mixed hidden Markov models with SAEM. Application to daily seizures data09:35-10:00Lay Ahyoung LimDose-response-dropout analysis for somnolence in Pregabalin-treated patients with generalized anxiety disorder10:00-10:05Presentation of Awards10:05-11:20Coffee break, Poster and Software session IIIPosters in Group III (see below) are accompanied by their presenter11:20-12:20Clinical applications of PK(PD)chair:  Dinesh de Alwis11:20-11:40Chao ZhangPopulation Pharmacokinetics of Lopinavir/Ritonavir in Combination with Rifampicin-based Antitubercular Treatment in HIV-infected Children 11:40-12:00Jeff BarrettEnhancing Methotrexate Pharmacotherapy in Children with Cancer: A Decision Support System Integrating Real-time PK/PD Modeling and Simulation with Patient Medical Records12:00-12:20Sarah McLeayExploring different body-size metric based dosing strategies for propofol in morbidly obese versus healthy weight subjects by modelling and simulation approach12:20-13:50Lunch13:50-15:15Integrating data with literaturechair: Lutz Harnisch 13:50-13:55Lutz HarnischIntroduction to integrating data with literature13:55-14:15Eugene CoxMeta- Analysis of Retention Rates of Post-Marketing Trials to Compare Effectiveness of Second Generation Antiepileptic Drugs14:15-14:35Rocío Lledó-GarcíaA mechanistic model of the steady-state relationship between HbA1c and average glucose levels in a mixed population of healthy volunteers and diabetic subjects14:35-15:15Jonathan FrenchWhen and how should I combine patient-level data and literature data in a meta-analysis?15:15-16:30Tea break, Poster and Software session IVPosters in Group IV (see below) are accompanied by their presenter16:30-17:10Designchair: Marylore Chenel 16:30-16:50Camille VongRapid sample size calculations for a defined likelihood ratio test-based power in mixed effects models16:50-17:10Lee Kien FooD-optimal Adaptive Bridging Studies in Pharmacokinetics19:00-01:00Social eveningFriday June 1109:00-10:00Stuart Beal Methodology Sessionchair: Oscar della Pasqua 09:00-09:20Marc LavielleMixture models and model mixtures with MONOLIX09:20-09:40Matthew HutmacherExtending the Latent Variable Model to Non-Independent Longitudinal Dichotomous Response Data09:40-10:00Elodie PlanAnalysis Approaches Handling Both Symptomatic Severity and Frequency10:00-10:10Preview of PAGE 201110:10-10:50Coffee Break10:50-12:10PKPD modelschair: Nick Holford 10:50-11:10Sylvain GoutelleMathematical modeling of pulmonary tuberculosis therapy: development of a first prototype model with rifampin11:10-11:30Alberto RussuIntegrated model for clinical response and dropout in depression trials: a state-space approach11:30-11:50Klas PeterssonPredictions of in vivo prolactin levels from in vitro Ki values of D2 receptor antagonists using an agonist-antagonist interaction model11:50-12:10Rada SavicAdherence and Population Pharmacokinetics of Atazanavir in Naïve HIV-Infected Patients using Medication Events Monitoring System (MEMS) for drug intake timing 12:10-12:20Closing Remarks12:20-12:50Audience Input for the PAGE 2011 Program 

Software demonstrations-Commercial

S_1: Stephane Vellay Pipeline Pilot - Data Integration, Analysis, and Reporting Platform
S_2: Masoud Jamei Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of drug absorption, tissue distribution, metabolism, transport and elimination in healthy and disease populations using in vitro knowledge
S_3: Sven Janssen SimBiology: A Graphical Environment for Population PK/PD

Software demonstrations-Non-commercial

S_10: Juergen Bulitta Development and Evaluation of a New Efficiency Tool (SADAPT-TRAN) for Model Creation, Debugging, Evaluation, and Automated Plotting using Parallelized S-ADAPT, Perl and R
S_11: Kajsa Harling Xpose and Perl speaks NONMEM (PsN)
S_12: Roger Jelliffe The MM-USCPACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens.
S_13: Ron Keizer Piraña: Open source modeling environment for NONMEM
S_14: Marc Lavielle Analysing population PK/PD data with MONOLIX 3.2
S_15: Sebastian Ueckert PopED - An optimal experimental design software

Posters Wednesday Morning (group I)

Applications- Anti-infectives
I_1: Bambang Adiwijaya Applications of Discrete-Event Dynamic Simulation in HCV Treatment Dynamics
I_2: Jurgen Bulitta Mechanism-based Modelling of the Synergy of Colistin Combinations against Multidrug-Resistant Gram Negative Bacteria
I_4: Emmanuel Chigutsa Parallel first order and mixed order elimination of pyrazinamide in South African patients with tuberculosis
I_5: Isabelle Delattre Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin in critically ill septic patients
I_6: Oleg Demin Application of systems pharmacology modeling approach to optimize Interferon therapy of hepatitis C
I_7: Thomas Dorlo Optimal Dosing of Miltefosine in Children and Adults with Leishmaniasis

Applications- Biologicals/vaccines
I_8: Marion Dehez Bayesian framework applied to dose escalation studies for biologics 
I_9: Amit Garg A Mechanism Based Population Pharmacokinetic-Pharmacodynamic Model for Epoetin Alfa and Darbepoetin Alfa in Chronic Kidney Disease Patients 
I_10: Kenneth Luu A Mechanistic Approach to Predicting Human Pharmacokinetics of Monoclonal Antibodies from Preclinical Data: A Case Example
I_11: David Ternant Methotrexate influences neither pharmacokinetics nor concentration-effect relationship of infliximab in axial ankylosing spondylitis
I_12: Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Anti-CD3 Monoclonal Antibody, Otelixizumab, in Subjects with Diabetes and Psoriasis 

Applications- CNS
I_13: Neil Attkins Model based analysis of antagonist binding kinetics at CRF-1 receptors in vitro and in vivo
I_14: Marcus Björnsson Modeling of Pain Intensity Measured on a Visual Analogue Scale and Informative Dropout in a Dental Pain Model after Naproxcinod and Naproxen Administration
I_15: Jacob Brogren Transit Compartment Model Useful for Describing Absorption of Quetiapine XR and IR
I_16: Yu-Yuan Chiu Population Pharmacokinetics of Lurasidone in Healthy Subjects and Subjects with Schizophrenia
I_17: Vincenzo Luca Di Iorio Impact of Seizures and Efflux Mechanisms on the Biophase Kinetics and CNS Effects of Anticonvulsant Drugs 

Applications- Oncology
I_18: Nicolas Azzopardi Pharmacokinetics and concentration-effect relationship of cetuximab in metastatic colorectal cancer
I_19: Anne Drescher Pharmacokinetic/Pharmacodynamic Modeling of Platinum-DNA-Adduct Formation in Leukocytes after Oxaliplatin Infusion
I_20: Jeroen Elassaiss-Schaap Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer
I_21: Iñaki F. Trocóniz Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies using diflomotecan and indisulam 
I_22: Ron Keizer Evaluation of clinical dosing of E7820 from preclinical and clinical data using a biomarker

Applications- Other topics
I_23: Claire Ambery Leveraging biomarker exposure-response in drug development
I_24: Jacqueline Anderson PK modelling of organophosphorus poisoning in humans
I_25: Massoud Boroujerdi Joint model for dropout in longitudinal trials in COPD patients
I_26: Karl Brendel Population pharmacokinetics-pharmacodynamics modeling of the QTc prolongation of Moxiflovoxacin and Levofloxacin in healthy volunteers: selection of the positive control in mandatory QT/QTc studies
I_27: Karl Brendel Using Modelling & Simulation techniques to optimise the design of a paediatric PK/PD study
I_28: Sophie Callies Integration of preclinical data to support the design of the first in-man study of LY2181308, a second generation antisense oligonucleotide.
I_29: Roosmarijn De Cock Predicting glomerular filtration rate using clearance of amikacin
I_30: Oleg Demin Jr Can systems modeling approach be used to understand complex PK-PD relationships? A case study of 5-lipoxygenase inhibition by zileuton
I_31: Pinky Dua SB-773812: Correlation between in-silico and in-vivo metabolism
  1   2   3   4   5   6   7   8   9   10   11


Coffee break, Poster and Software session I icon10: 30 11: 00am Coffee Break Tuesday 11: 00am 12: 30pm

Coffee break, Poster and Software session I icon10: 30 to 11: 00am Coffee Break Tuesday 11: 00am 12: 30pm

Coffee break, Poster and Software session I iconPoster Session I: Wednesday 10: 15-11: 45

Coffee break, Poster and Software session I iconPoster Session 1: Wednesday, 15 May 2002 – 17. 30-19. 00

Coffee break, Poster and Software session I iconGeneral poster session commission (AP)

Coffee break, Poster and Software session I iconConference contributions ordered by session themes – podium, panel and poster presentations

Coffee break, Poster and Software session I iconСтендовая сессия poster session Универсальный выставочный зал
Примечание: индексом «С» обозначены работы, представленные на конкурс молодых ученых
Coffee break, Poster and Software session I iconI am thinking of starting a coffee roasting business, and I am doing some market research. What brand of ground coffee had the largest market share in the

Coffee break, Poster and Software session I iconCoffee Afternoons Summer is almost over and Coffee Afternoons will start again on the 25th September and continue at the King Street Hall

Coffee break, Poster and Software session I iconProductivity and Quality in Software-Projects Psychological Analyses and Optimization of Work Processes in Software-Development

Разместите кнопку на своём сайте:

База данных защищена авторским правом © 2014
обратиться к администрации
Главная страница